January 30, 2024
Damon R. Race, President & CEO
RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend the BIO CEO & Investor Conference, which will be held in New York, NY from February 26-27, 2024. GeneVentiv will meet with prospective investors, to share news and present GENV-HEM, GeneVentiv’s lead AAV-based gene therapy which has an FDA Orphan Drug Designation for hemophilia A or B with or without inhibitors.
GeneVentiv Therapeutics is a pre-clinical gene therapy company focused on blood disorders. Our lead program, GENV-HEM (AAV8.FVa), is the only single infusion, universal, AAV-based gene therapy able to treat all types of hemophilia. Unlike other AAV-based hemophilia gene therapies, GENV-HEM is the only gene therapy able to treat the 33% of hemophilia patients with neutralizing antibodies (inhibitors) to their missing clotting factor. There are 50,000 inhibitor patients in the developed world. Approved, single infusion, gene therapies for non-inhibitor patients are priced between $2.9M and $3.5M. GENV-HEM has received Orphan Drug Designation from the FDA for Hemophilia A and B with or without inhibitors and a Letter of Support from the National Bleeding Disorders Foundation.